Skip to main content
RAPP
NASDAQ Life Sciences

Rapport Therapeutics Q2 2026: Cash Runway Extended to H2 2029, Phase 3 FOS Trial Underway

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Neutral
Importance info
7
Price
$40.51
Mkt Cap
$2.018B
52W Low
$13.62
52W High
$44.28
52W Position info
197% above low
Off High info
8.5% below high
Rel. Volume info
1.1× avg
Market data snapshot near publication time

RAPP has more than doubled off its 52-week low of $13.62.

Summary

Rapport Therapeutics' Q2 2026 10-Q shows a $56.6M net loss, $436.1M in cash extending runway to H2 2029, and the launch of Phase 3 trials for its lead epilepsy drug. Phase 2 bipolar mania data is expected in October 2026.


Key Events · Earnings and Guidance · RAPP

  • Cash Runway Extended to H2 2029

    Cash, cash equivalents and short-term investments totaled $436.1 million as of June 30, 2026, funding operations into the second half of 2029.

  • Phase 3 FOS Trial Initiated

    The Phase 3 program for RAP-219 in drug-resistant focal onset seizures began in Q2 2026, following positive Phase 2a data and FDA feedback.

  • Phase 2 Bipolar Mania Data in October 2026

    Topline results from the Phase 2 proof-of-concept trial of RAP-219 in bipolar mania are expected in October 2026, with the trial potentially serving as confirmatory evidence.

  • RAP-219 Half-Life Updated to 22 Days

    Pharmacokinetic modeling now estimates a 22-day half-life for RAP-219, up from 14 days, supporting sustained receptor occupancy and durable clinical responses.


Analysis · RAPP · Life Sciences

A net loss of $56.6 million marked Rapport Therapeutics' second quarter of 2026, fueled by a sharp rise in R&D spending as the company launched its Phase 3 program for RAP-219 in drug-resistant focal onset seizures. Closing the quarter with $436.1 million in cash and investments extends the runway into the second half of 2029 — a critical buffer for a pre-revenue biotech advancing multiple late-stage trials. The Phase 2 bipolar mania trial remains on track for topline data in October 2026, a near-term catalyst. The filing also disclosed an updated 22-day half-life for RAP-219, supporting sustained efficacy, and an amended director compensation policy. While the loss widened year-over-year, the strong cash position and clinical execution reinforce the investment thesis.

How filings like this one have moved

In the 30 days to Nov 15, 2026, 37.5% of the 3713 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, RAPP was trading at $40.51 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2B. The 52-week trading range was $13.62 to $44.28. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

RAPP - Latest Insights

RAPP
Nov 04, 2026, 7:12 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $25.48
Real-time Price: $26.00 info
Change: +$0.520 (+2%) info
Market Cap: $1.55B info
RAPP
Oct 30, 2026, 7:32 PM EDT
Filing Type: 4
Importance Score:
8
Price at Filing: $24.56
Real-time Price: $26.00 info
Change: +$1.44 (+6%) info
Market Cap: $1.55B info
RAPP
Oct 30, 2026, 5:12 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $25.56
Real-time Price: $26.00 info
Change: +$0.4429 (+2%) info
Market Cap: $1.55B info
RAPP
Oct 30, 2026, 7:04 AM EDT
Filing Type: 424B5
Importance Score:
8
Price at Filing: $22.55
Real-time Price: $26.00 info
Change: +$3.45 (+15%) info
Market Cap: $1.55B info
RAPP
Oct 28, 2026, 6:18 AM EDT
Filing Type: FWP
Importance Score:
8
Price at Filing: $21.80
Real-time Price: $26.00 info
Change: +$4.20 (+19%) info
Market Cap: $1.55B info